| Market Research A to Z | Company Profiles A to Z | Register | Contact Us |
| +44 (0) 203 086 8600 Call us on |
United States Pharmaceuticals and Healthcare Report Q4 2009
Market |
Healthcare and Medical |
Report Type |
Market Research |
Country |
United States |
Published |
8 October 2009 |
Number of Pages |
102 |
Download |
|
Immediate |
|
Publisher |
Business Monitor International |
US Healthcare spending in 2008 reached US$2.3 trillion, while sales of pharmaceuticals topped US$309 billion
Despite a downturn in growth rates in the US pharmaceuticals & healthcare markets, the country remains a core component for any company looking to achieve global success. Healthcare spending in 2008 reached US$2.3trn, while sales of pharmaceuticals topped US$309bn. For BMI’s US Pharmaceuticals & Healthcare Report Q409, our new 10-year Drug Expenditure Model has been introduced, giving a longer-term view of potential for sales. By 2018 BMI forecasts that pharmaceutical expenditure will be approaching US$400bn, representing a compound annual growth rate (CAGR) of 2.5%. This, combined with the US’s strong regulatory environment, stable political and economic environment and country structure-related opportunities mean that the country is ranked first globally within our Business Environment Ratings.
Much is currently at stake in the US pharmaceutical & healthcare industry. President Barack Obama’s healthcare reform is set to dramatically change the industry landscape over the next few years. Among the proposals are: the possible introduction of a government health insurer, which would place significant downward pressures on prices; reviewing the length of exclusivity for biologics and entry for biosimilars, which could tilt the balance of generic and patented market growth; the level of prescription coverage enacted under any universal insurance model; and the introduction of re-imported drug legislation. Patent expiries for many high value products are set to significantly erode sales for many major pharmaceutical companies. However, due to the complexity of patent files and litigation efforts, calculating the exact entry for generic medicines can be troublesome. The possible ban of pay-to-delay settlements and authorised generics could also provide a major downside for patented drugs.
The shape of economic recovery in the US will also have a major bearing on market dynamics, particularly in the case of over-the-counter (OTC) medicines or prescription drugs, which require substantial co-payments. The epidemiological profile of the US resembles that of many developed states. BMI’s Burden of Disease Database (BoDD) reveals that of the 37.76mn disability-adjusted life years (DALYs) lost to all diseases and injuries in 2008, just 5.13% were accountable to communicable diseases. This is fairly typical for a developed state and is a reflection of the US’s generally high access to basic medical care and the effects of Westernised lifestyles causing an increase in the burden of non-communicable diseases, despite beneficial developments in medicine and medical technology.
Last Viewed
United States Pharmaceuticals and Healthcare Report Q4 2009Infantswear - BRIC - Brazil, Russia, India, China - Industry Guide
AEON Company Ltd - 2009 Fortune Global 500 Company Snapshot
Pactiv Corporation - Financial and Strategic Analysis Review
Kobayashi Pharmaceutical Co Ltd - Financial Analysis Review
Healthcare and Medical Company Profiles
Healthcare and Medical Company Profiles contain up to date financial, strategic, operational, SWOT analysis and product information on the activities of thousands of healthcare and medical companies.
Become an Affiliate
Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?
Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website. If a sale is made from your visitor, you earn commission (a fixed percentage of the price of a product).
Custom Research
Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.
News
Genium Bionic Prosthetic System Represents the First Intuitive Knee
AdCare continues nursing facilities acquisitions strategy
AdCare Purchases US$27.3Mn Nursing Facilities in Arkansas to Drive Strong Revenue Growth
Micromet to Develop Blinatumomab with the National Cancer Institute
AstraZeneca to Develop Targacept’s Product Candidate AZD1446 as a Treatment for Alzheimer’s
Market Insights
Currently there are no Market Insights in this sector.
